Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Thrombolytic agents and anticoagulants.

Literature DB >> 8110627

Thrombolytic agents and anticoagulants.

Abstract

The medical and scientific communities, appreciating the pivotal role of thrombosis in the evolution and expression of atherosclerotic coronary artery disease, have embarked upon intense efforts to develop safe, effective, and affordable thrombolytic agents and anticoagulants. With an understanding that more is not always better, these new compounds, mutants, and derivatives will be designed specifically to impair, neutralize, or enhance several key components of well-characterized thrombotic and fibrinolytic processes. If efforts continue at the current pace, one or more "designer" thrombolytics and anticoagulants will be ready for Phase II or Phase III clinical trials in the near future.

Entities: Disease

Mesh：

Substances：

Year: 1993 PMID： 8110627 DOI： 10.1007/bf00878937

Source DB: PubMed Journal: Cardiovasc Drugs Ther ISSN： 0920-3206 Impact factor: 3.727

17 in total

1. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.

Authors: T R Hare; S J Gardell
Journal: Thromb Haemost Date: 1992-08-03 Impact factor: 5.249

Review 2. Anticoagulant and antithrombotic actions of recombinant hirudin.

Authors: B Kaiser
Journal: Semin Thromb Hemost Date: 1991-04 Impact factor: 4.180

3. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis.

Authors: M Heras; J H Chesebro; M W Webster; J S Mruk; D E Grill; W J Penny; E J Bowie; L Badimon; V Fuster
Journal: Circulation Date: 1990-10 Impact factor: 29.690

4. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.

Authors: D Collen; M Dewerchin; H J Rapold; H R Lijnen; J M Stassen
Journal: Circulation Date: 1990-11 Impact factor: 29.690

5. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.

Authors: D Collen; H R Lu; H R Lijnen; L Nelles; J M Stassen
Journal: Circulation Date: 1991-09 Impact factor: 29.690

6. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.

Authors: H R Lijnen; J M Stassen; I Vanlinthout; H Fukao; K Okada; O Matsuo; D Collen
Journal: Thromb Haemost Date: 1991-10-01 Impact factor: 5.249

7. An anti-tissue factor monoclonal antibody which inhibits TF.VIIa complex is a potent anticoagulant in plasma.

Authors: W Ruf; T S Edgington
Journal: Thromb Haemost Date: 1991-11-01 Impact factor: 5.249

8. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.

Authors: H R Lu; Z Wu; P Pauwels; H R Lijnen; D Collen
Journal: J Am Coll Cardiol Date: 1992-05 Impact factor: 24.094